Overview
SenseDose Technologies is an India-based healthcare start-up working to improve adherence to medication by using IOT-based technology. The company is primarily focused on the Indian market currently. SenseDose’s primary product is TMEAD (Tuberculosis Monitoring Encouragement Adherence Drive), a device that is part medication manager and part adherence solution.
How it works
TMEAD is a reusable pill dispenser composed of two key parts, a durable dispenser and communication cartridge. The cartridges are pre-loaded with a patient’s medication that are separated into discrete packages. When a patient takes their medication from the dispenser, the adherence event is logged and reported via SIM card.
Scoring
TMEAD has been scored below according to it’s ability to serve the TB market for low- and middle-income countries (LMICs) along Fit for Purpose and Technical Specifications metrics. Note that higher scores equate to a greater ability to serve the market. For example, if a product scores well in the Provider Burden subcategory, that means that the burden for the provider is low.
For full descriptions of the sub-categories, see the 2021 DAT Market Landscape.
Fit for Purpose
Technical Specifications
Advantages
- Patient burden is extremely low. Medication is already organized and ready to be dispensed
- Can be pre-loaded with 15 days of medication and can dispense 18 tablets at a time
- Use of phone/app is optional
- Rechargeable battery holds charge for 30 days
Disadvantages
- Device is not particularly portable.
- Requires significant pharmacy or back-end work to load cartridges.
- Requires adapting existing supply chains.
Access
For more information on the T-MEAD, please visit the SenseDose Technologies website.